摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-methyl-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine dihydrochloride | 1451391-78-8

中文名称
——
中文别名
——
英文名称
N-methyl-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine dihydrochloride
英文别名
N-Methyl-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine hydrochloride;N-methyl-N-(oxan-4-yl)piperidin-4-amine;hydrochloride
N-methyl-N-(tetrahydro-2H-pyran-4-yl)piperidin-4-amine dihydrochloride化学式
CAS
1451391-78-8
化学式
C11H22N2O*2ClH
mdl
——
分子量
271.23
InChiKey
KOZMIXSBWUILLW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.27
  • 重原子数:
    15
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    24.5
  • 氢给体数:
    2
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Structure−Activity Relationships of 6-Methyl-benzo[b]thiophene-2-carboxylic Acid (1-{(S)-1-Benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl}cyclopentyl)amide, Potent Antagonist of the Neurokinin-2 Receptor
    摘要:
    As part of a project aimed at the identification of a series of small, orally available antagonists for the hNK(2) receptor, starting from one of our capped dipeptide libraries, we succeeded in the chemical optimization of the first identified leads, finally producing a class of molecules with significant activity in our animal model after iv administration. We herein report the results of further chemical modifications made to reduce the overall peptide character of this series and the consequent improvement of their in vivo antagonist activity. The present work identified 6-methylbenzo[b]thiophene-2-carboxylic acid (1-{(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl}cyclopentyl)amide (10i), endowed with subnanomolar potency in all the in vitro tests and being highly potent and of long duration upon in vivo testing after both iv and id dosing.
    DOI:
    10.1021/jm100176s
  • 作为产物:
    参考文献:
    名称:
    [EN] CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD
    [FR] PYRIMIDINE-4 CARBOXAMIDES CYCLIQUES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CCR2 POUR LE TRAITEMENT D'INFLAMMATIONS, DE L'ASTHME ET DES BRONCHO-PNEUMOPATHIES CHRONIQUES OBSTRUCTIVES
    摘要:
    本发明涉及用于治疗疾病和疾病的新型CCR2(CC趋化因子受体2)拮抗剂及其用途,特别是用于治疗肺部疾病如哮喘和慢性阻塞性肺病的药物。公式(I),其中A从单键,=CH-,-CH2-,-O-,-S-和-NH-中选择;其中n为1、2或3;其中Z为C或N,其他变量如声明中所定义,以及以药理学上可接受的酸的酸盐形式存在。
    公开号:
    WO2010070032A1
点击查看最新优质反应信息

文献信息

  • Structure−Activity Relationships of 6-Methyl-benzo[<i>b</i>]thiophene-2-carboxylic Acid (1-{(<i>S</i>)-1-Benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl}cyclopentyl)amide, Potent Antagonist of the Neurokinin-2 Receptor
    作者:Daniela Fattori、Marina Porcelloni、Piero D’Andrea、Rose-Marie Catalioto、Alessandro Ettorre、Sandro Giuliani、Elena Marastoni、Sandro Mauro、Stefania Meini、Cristina Rossi、Maria Altamura、Carlo A. Maggi
    DOI:10.1021/jm100176s
    日期:2010.5.27
    As part of a project aimed at the identification of a series of small, orally available antagonists for the hNK(2) receptor, starting from one of our capped dipeptide libraries, we succeeded in the chemical optimization of the first identified leads, finally producing a class of molecules with significant activity in our animal model after iv administration. We herein report the results of further chemical modifications made to reduce the overall peptide character of this series and the consequent improvement of their in vivo antagonist activity. The present work identified 6-methylbenzo[b]thiophene-2-carboxylic acid (1-(S)-1-benzyl-4-[4-(tetrahydropyran-4-ylmethyl)piperazin-1-yl]butylcarbamoyl}cyclopentyl)amide (10i), endowed with subnanomolar potency in all the in vitro tests and being highly potent and of long duration upon in vivo testing after both iv and id dosing.
  • [EN] CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD<br/>[FR] PYRIMIDINE-4 CARBOXAMIDES CYCLIQUES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR CCR2 POUR LE TRAITEMENT D'INFLAMMATIONS, DE L'ASTHME ET DES BRONCHO-PNEUMOPATHIES CHRONIQUES OBSTRUCTIVES
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2010070032A1
    公开(公告)日:2010-06-24
    The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. Formula (I), wherein A is selected from among a single bond, =CH-, -CH2-, -O-, -S-, and -NH-; wherein n is 1, 2 or 3; wherein Z is C or N, the other variables are as defined in the claims, as well as in form of their acid addition salts with pharmacologically acceptable acids.
    本发明涉及用于治疗疾病和疾病的新型CCR2(CC趋化因子受体2)拮抗剂及其用途,特别是用于治疗肺部疾病如哮喘和慢性阻塞性肺病的药物。公式(I),其中A从单键,=CH-,-CH2-,-O-,-S-和-NH-中选择;其中n为1、2或3;其中Z为C或N,其他变量如声明中所定义,以及以药理学上可接受的酸的酸盐形式存在。
查看更多